Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3931-3940 Newer>

The Motley Fool July 30, 2007 Brian Orelli	Glaxo Puffs Up Targacept In the weird world of drug partnerships, GlaxoSmithKline, maker of antismoking nicotine patches, is teaming up with Targacept to investigate the positive effects of nicotine. Investors, take note.
The Motley Fool July 30, 2007 Brian Orelli	Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
The Motley Fool July 30, 2007 Brian Lawler	AtheroGenics Follows a New Route AtheroGenics gives more details on the path forward for its lead drug. The drugmaker is trading at a low $70 million valuation, but investors who buy into shares today shouldn't get their hopes up for the outcome.
The Motley Fool July 30, 2007 Brian Orelli	Mega Mylan Is on Track Comparing year-over-year results for Mylan will continue to be complicated for the next year and a half or so. It's one merger down, one to go for the generic drug company. Investors, take note.
The Motley Fool July 30, 2007 Brian Lawler	Is Glaxo's Avandia Down for the Count? An FDA advisory committee is set to debate one of Glaxo's top compounds. What will it mean to investors?
The Motley Fool July 30, 2007 Brian Lawler	Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better.
BusinessWeek August 6, 2007 John Carey	When Medical Studies Collide Contradictory reports? The world of medical and health research is messier than most people realize.
The Motley Fool July 27, 2007 Brian Lawler	Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance.
The Motley Fool July 27, 2007 Brian Lawler	Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too.
<Older 3931-3940 Newer> Return to current articles.